Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Renata Pazdírková
Efficacy, Safety and Population Pharmacokinetics of Sapropterin in PKU Patients <4 Years: Results From the SPARK Open-Label, Multicentre, Randomized Phase IIIb Trial
Orphanet Journal of Rare Diseases
Medicine
Genetics
Pharmacology
Related publications
Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial
SKIN The Journal of Cutaneous Medicine
Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study
Clinical Therapeutics
Pharmacology
Single-Dose Pharmacokinetics of Co-Crystal of Tramadol-Celecoxib: Results of a 4-Way Randomized Open-Label Phase I Clinical Trial in Healthy Subjects
British Journal of Clinical Pharmacology
Pharmacology
Efficacy, Safety and Pharmacokinetics of Subcutaneous Azacitidine in Chinese Patients With Higher Risk Myelodysplastic Syndromes: Results From a Multicenter, Single-Arm, Open-Label Phase 2 Study
Asia-Pacific Journal of Clinical Oncology
Medicine
Oncology
Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study
Journal of the American Academy of Dermatology
Dermatology
A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain
Current Oncology
Oncology
Safety and Efficacy of Intrarenal Arterial Autologous CD34+ Cell Transfusion in Patients With Chronic Kidney Disease: A Randomized, Open-Label, Controlled Phase II Clinical Trial
Stem cells translational medicine
Medicine
Developmental Biology
Cell Biology
Safety and Efficacy of Pasireotide in Dumping Syndrome-Results From a Phase 2, Multicentre Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Trial Design of Phase IIIb, Open-Label, Single Arm Study to Evaluate Efficacy and Safety of Pasireotide LAR in Patients With Inadequately-Controlled Acromegaly Despite Treatment With First-Generation Somatostatin Analogues
Endocrine Abstracts